Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Benralizumab 30mg/mL; soln for SC inj; preservative-free.

Select therapeutic use:

Indications for FASENRA:

As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.

Limitations Of use:

Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.


Give by SC inj into upper arm, thigh, or abdomen. 30mg once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter.


Not established.


Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Treat pre-existing helminth infections before initiating therapy; discontinue Fasenra if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Fasenra initiation, if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-5 antagonist.

Adverse Reactions:

Headache, pharyngitis, pyrexia, hypersensitivity reactions.

Generic Availability:


How Supplied:

Single-dose prefilled syringe—1

FASENRA 30mg/ml syringes (Qty:1)

appx. price $5589.00